TriangleNCT00408005 · OUTCOME
Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years from randomization at the end of induction
What was measured
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.
Analysis population: Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Nelarabine versus No Nelarabine. T-LLY patients are excluded from this analysis. Induction failures non-randomly assigned to Arm IV were excluded from this analysis.
Groups in this outcome
ARM I (Combination Chemotherapy)
No Nelarabine, Capizzi Methotrexate
ARM II (Combination Chemotherapy)
Nelarabine, Capizzi Methotrexate
ARM III (Combination Chemotherapy)
No Nelarabine, High-Dose Methotrexate
ARM IV (Combination Chemotherapy)
Nelarabine, High-Dose Methotrexate
| Group | Source count |
|---|---|
| ARM I (Combination Chemotherapy) | 151 |
| ARM II (Combination Chemotherapy) | 147 |
| ARM III (Combination Chemotherapy) | 185 |
| ARM IV (Combination Chemotherapy) | 176 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ARM I (Combination Chemotherapy) | 89.01 | Not reported | 83.4 | 94.6 | Not reported |
| ARM II (Combination Chemotherapy) | 90.53 | Not reported | 85.0 | 96.0 | Not reported |
| ARM III (Combination Chemotherapy) | 78.07 | Not reported | 71.2 | 84.9 | Not reported |
| ARM IV (Combination Chemotherapy) | 86.46 | Not reported | 80.6 | 92.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 83.4
- upper Limit
- 94.6
- value
- 89.01
- group Id
- OG001
- lower Limit
- 85.0
- upper Limit
- 96.0
- value
- 90.53
- group Id
- OG002
- lower Limit
- 71.2
- upper Limit
- 84.9
- value
- 78.07
- group Id
- OG003
- lower Limit
- 80.6
- upper Limit
- 92.4
- value
- 86.46
- denoms
- counts
- group Id
- OG000
- value
- 151
- group Id
- OG001
- value
- 147
- group Id
- OG002
- value
- 185
- group Id
- OG003
- value
- 176
- units
- Participants
- description
- Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- No Nelarabine, Capizzi Methotrexate
- id
- OG000
- title
- ARM I (Combination Chemotherapy)
- description
- Nelarabine, Capizzi Methotrexate
- id
- OG001
- title
- ARM II (Combination Chemotherapy)
- description
- No Nelarabine, High-Dose Methotrexate
- id
- OG002
- title
- ARM III (Combination Chemotherapy)
- description
- Nelarabine, High-Dose Methotrexate
- id
- OG003
- title
- ARM IV (Combination Chemotherapy)
- param Type
- NUMBER
- population Description
- Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Nelarabine versus No Nelarabine. T-LLY patients are excluded from this analysis. Induction failures non-randomly assigned to Arm IV were excluded from this analysis.
- reporting Status
- POSTED
- time Frame
- 4 years from randomization at the end of induction
- title
- Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
- type
- PRIMARY
- unit Of Measure
- percent probability
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice